Navigation Links
Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia
Date:12/8/2009

lly well tolerated in the study.(1) A small number of patients discontinued due to adverse events.(1)

"The impressive rates of response observed in this study, combined with the very low rate of disease progression seen in nilotinib-treated patients are very encouraging," said Professor Richard Clark, Consultant Haematologist at Royal Liverpool University Hospital and a trialist involved in this study. "Continued improvement in the treatment of Ph+ CML is very important and these results indicate that nilotinib may provide long-term improvement in progression-free survival."

95% of patients with CML have an abnormality known as the Philadelphia chromosome. This chromosome produces a type of protein called Bcr-Abl, which is responsible for the overproduction of the cancerous white blood cells that are the main feature in Ph+ CML.(3) Nilotinib is a potent and selective inhibitor of the Bcr-Abl protein, thereby inhibiting the production of these cancerous cells.(4,5)

"Novartis has been at the forefront of research on the molecular origin of Ph+ CML and this has led to the development of treatments with unprecedented effectiveness and safety," said Panos Alexakos, Oncology Business Unit Head for Novartis UK. "These data are exciting and the deeper molecular response demonstrated provides hope for further improvement in outcomes for patients with Ph+ CML in the future."

Novartis plans to file worldwide applications for approval of nilotinib as a treatment for adult patients with newly diagnosed Ph+ CML. Nilotinib is currently approved in more than 80 countries including the European Union (EU), United States and other countries for the treatment of adult patients with Ph+ CML in chronic phase or accelerated phase who are resistant or intolerant to prior treatment including imatinib.

Notes to editors

Study details

The clinical trial, Evaluating Nilot
'/>"/>

SOURCE Novartis Oncology
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... -- Hospira, Inc. (NYSE: HSP ), ... spoke about the importance of extrapolation in bringing biosimilars ... annual European Biosimilars Group conference in London ... publication of a pivotal white paper titled, "Why ... biosimilars." Speaking at the EGA conference, ...
(Date:4/23/2015)... , April 24, 2015  AbbVie (NYSE: ABBV ... Administration (FDA) has accepted its New Drug Application (NDA) ... two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), ... of adults with chronic genotype 4 (GT4) hepatitis C ... first all-oral, interferon-free therapy being evaluated by the FDA ...
(Date:4/23/2015)... 23, 2015 Once again, BeaconMedaes is meeting ... to patient safety. BeaconMedaes, priority is to ... disease. The next generation Zone Valve Box ... are now mounted in the assembly, allowing for ease ... ceiling tiles potentially releasing dust spores and other bacteria ...
Breaking Medicine Technology:Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2
(Date:4/27/2015)... The Radiology Business Management Association ... applied business information and intelligence, is proud to announce ... newsletter for its more than 2,000 members. , “RBMA ... news sources in that it is exclusively devoted to ... radiology. The newsletter is produced in cooperation with Thorn ...
(Date:4/27/2015)... Doping has been around sports for years ... continue to capture the public’s imagination, but so-called smart ... performance enhancement along with new ethical considerations. In an ... Anjan Chatterjee of Pennsylvania Hospital and the ... of these enhancements in sports. , Chatterjee studies the ...
(Date:4/27/2015)... 2015 Jvion, the Atlanta-based leader in ... and recognized as one of the top 40 fastest ... is presented by the Atlanta Business Chronicle, honors Atlanta’s ... status as an economic capital and employment hub. , ... spurred by the growing need to improve healthcare quality ...
(Date:4/26/2015)... Indianapolis, Indiana (PRWEB) April 26, 2015 ... network service provider announces that Brotherhood Mutual Insurance Company ... Daniel Armstrong, Manager of Network Infrastructure at Brotherhood Mutual ... value and the service reliability Brotherhood Mutual needed. ... route diversity, and IFN worked with us to ensure ...
(Date:4/26/2015)... This annual celebration is one of the ... include a spectacular collection of vendors offering distinctive gifts ... incense, chimes, vases, candleholders, fleece throws, trivets, jewelry and ... collection of vendors, guests will have the opportunity to ... Jimmie Jazz Band. , “We are ecstatic to ...
Breaking Medicine News(10 mins):Health News:Radiology Business Management Association Launches Weekly Legislative and Policy Newsletter 2Health News:The Brain, Smart Drugs, and Sports on SCI TV with Anjan Chatterjee 2Health News:The Brain, Smart Drugs, and Sports on SCI TV with Anjan Chatterjee 3Health News:Jvion Named to Top 40 Atlanta 2015 Pacesetters 2Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 2Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 3Health News:It’s Coming! The 5th Annual Tulip Festival & Mother’s Day Celebration at Honor's Haven Resort & Spa! 2
... Pays Cash When You Are Sick or Hurt?COLUMBUS, Ga., March 2 ... Aflac Duck as the mystery benefactor to policyholders who ... humorously shows how Aflac pays cash benefits when a medical ... night in a dark parlor. A group of friends is comforting ...
... March 2 DATATRAK International, Inc. (Nasdaq: ... global eClinical solutions for the clinical trials industry, today ... of Research and Development. In his role as DATATRAK,s ... to Raymond J. Merk, DATATRAK,s Chief Financial Officer and ...
... LCA-Vision Inc. (Nasdaq: LCAV ), a ... Plus (R) brand, today announced that members of its executive ... Institutional Investors Conference on Monday, March 9, 2009 at 8:40 ... The JW Marriott Grande Lakes Hotel in Orlando, Fla. ...
... study of children ages 8-11 years shows contact ... Athletic Competence, and Social Acceptance , JACKSONVILLE, ... benefits to children beyond simply correcting their nearsightedness ... physical appearance, acceptance among friends, and ability to ...
... Workplace Awards, Ten Honored for Best PracticesWASHINGTON, March ... can be felt across all industries, workplaces that ... times reap rewards for employer and employees alike, ... Psychologically Healthy Workplace Awards ceremony yesterday. Five organizations ...
... its 15,000th wish this summer , ... Pickering, ON, (PRWEB) March 2, ... three and 17 are diagnosed with a life-threatening illness. Every day more ... the efforts of The Children,s Wish Foundation of Canada and ...
Cached Medicine News:Health News:New Aflac Commercial Asks, 'Who Dun It?' 2Health News:New Aflac Commercial Asks, 'Who Dun It?' 3Health News:DATATRAK International, Inc. Announces the Return of Chris Wilke as Vice-President of R&D and the Issuance of a Patent 2Health News:DATATRAK International, Inc. Announces the Return of Chris Wilke as Vice-President of R&D and the Issuance of a Patent 3Health News:Children's Self-Perceptions Improve More With Contact Lenses vs. Glasses 2Health News:Children's Self-Perceptions Improve More With Contact Lenses vs. Glasses 3Health News:Children's Self-Perceptions Improve More With Contact Lenses vs. Glasses 4Health News:Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever 2Health News:Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever 3Health News:Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever 4Health News:Children's Wish, Canada's National Wish Granting Foundation Celebrates 25 Years 2Health News:Children's Wish, Canada's National Wish Granting Foundation Celebrates 25 Years 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: